Relay Therapeutics, Inc. 4

Relay Therapeutics CFO Thomas Catinazzo sold 17,717 shares of common stock at about $18.69 per share under a 10b5-1 plan, leaving him with 159,744 shares owned.

On July 6, 2026, Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo sold 17,717 shares of the company’s common stock at a weighted average price of approximately $18.69 per share under a pre-arranged Rule 10b5-1 trading plan adopted on October 30, 2025, for total proceeds of about $331,000. The transaction was executed in multiple trades within a price range of $18.39 to $19.38. Following this planned sale, Catinazzo reported beneficial ownership of 159,744 shares of Relay Therapeutics common stock, which includes 9,807 shares underlying restricted stock units, representing a holding valued at roughly $2.99 million based on the reported transaction price.

Filing Facts

CIK

1812364

Ticker

RLAY

Form

4

Source Type

fda

Accession

0001193125-26-298679

Alert Tier

6